Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Thanks to their specificity and stability in the sera, autoantibodies (AAbs) against tumor-associated antigens (TAAs) are very attractive biomarkers for the development of less invasive serological tests for the diagnosis and prognosis of cancer. Heat shock proteins (HSP) belong to TAAs and they are over-expressed in various human cancers. Elevated HSP can stimulate the immune system to produce anti-HSP antibodies. So far, AAbs against HSP have been identified in the circulation of various cancer patients. Here we will review current literature on the use of anti-HSP antibodies for cancer diagnosis and prognosis. The challenges as well as future directions of AAbs identification in oncology are also discussed.

Original publication

DOI

10.3233/CBM-160117

Type

Journal article

Journal

Cancer Biomark

Publication Date

2017

Volume

18

Pages

105 - 116

Keywords

Heat shock proteins, autoantibodies, cancer, diagnosis, prognosis, Antigens, Neoplasm, Autoantibodies, Biomarkers, Tumor, Enzyme-Linked Immunosorbent Assay, Heat-Shock Proteins, Humans, Neoplasms